Tilray Brands, Inc. (TLRY) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several positive elements: strong growth in Canadian and European markets, strategic international expansion, and a focus on higher-margin opportunities. The Q&A session further supports this with insights into market share gains, price stabilization, and a promising outlook for CC Pharma. Despite some challenges in the beer segment, the company's diversified strategy and international growth potential present a positive sentiment. Given the market cap, these factors suggest a likely positive stock price movement in the short term.
Key Financial Performance
Q2 Net Revenue $218 million, a record high. This represents a strong performance despite headwinds.
Adjusted EBITDA $8.4 million. This reflects operational improvements and cost management.
Adjusted EPS Loss $0.02, reflecting a reverse stock split adjustment.
Adjusted Cash Operating Income $6 million, indicating positive cash flow management.
International Cannabis Revenue $20 million, a 51% sequential growth and 36% year-over-year increase. Growth driven by international market expansion and operational improvements.
Cash and Marketable Securities $292 million, with a net cash position exceeding debt by $30 million. This reflects a strengthened balance sheet.
Canadian Adult-Use Cannabis Revenue $46 million, with a 6% growth in recreational cannabis sales. Growth attributed to product mix and market leadership.
Beverage Revenue $50 million, impacted by craft beer segment headwinds and portfolio optimization efforts.
Wellness Revenue $14.6 million, flat year-over-year. Growth in HiBall and ingredient channels offset by challenges in club retail.
Distribution Revenue $85 million, a 26% year-over-year increase. Growth driven by competitive pricing, portfolio optimization, and favorable foreign exchange impacts.
Gross Margin 26%, with increases in cannabis, distribution, and wellness segments. Beverage segment margins were temporarily impacted.
Net Loss $43.5 million, a 49% improvement year-over-year. Reflects operational improvements and cost management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New product launch: Introduced Redecan Amped Live Resin Liquid Diamond vapes in Canada, combining 80% live resin with 20% liquid diamonds for high potency and natural flavor. Entered Quebec market with Good Supply brand vapes, achieving top 3 SKU positions.
Beverage innovation: Launched non-alcoholic beverages under Montauk, 10 Barrel, and ready-to-drink canned beverages. Expanded HiBall clean energy drink to the U.K. and planned expansion to the Middle East and Africa.
Global cannabis market expansion: International cannabis revenue grew 36% YoY and 51% sequentially, driven by growth in Europe, particularly Germany, the U.K., and Poland. Expanded pharmacy reach in Germany to triple medical cannabis distribution footprint in fiscal 2026.
Beverage market expansion: Participated in the American Craft Beer Expo in Japan and gained insights for future growth. Expanded beverage business into new international markets, focusing on craft beer and non-alcoholic drinks.
Operational efficiency in beverages: Achieved $27 million in annualized cost savings in the first half of the year under Project 420, targeting $33 million by year-end.
Cannabis cultivation efficiency: Restarted outdoor cannabis grow in Cayuga, Ontario, increasing cultivation capacity to 200 metric tons annually, reducing costs and improving profit margins.
Regulatory readiness: Prepared for U.S. cannabis rescheduling to Schedule III, positioning for federally compliant medical cannabis framework. Leveraged regulatory experience and operational capabilities for immediate action.
Canadian regulatory advocacy: Advocated for modernization of Canadian cannabis regulations, including excise tax reform and integration of cannabis into healthcare, to maintain global competitiveness.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Challenges: Ongoing permit challenges and regulatory transitions in Portugal and Germany are impacting operations. Additionally, the lack of regulatory reform in Canada, including excise tax issues and restrictions on cannabis drinks in liquor stores, poses risks to the Canadian cannabis market.
Price Compression: Continued price compression, especially in flower products, is affecting profitability in the cannabis segment.
Supply Chain and Operational Risks: Scaling back supply in the Canadian wholesale market to prioritize higher-margin international markets could lead to supply chain inefficiencies. Additionally, operational challenges in integrating acquired beverage brands and optimizing processes are ongoing.
Market Headwinds in Craft Beer: Category-wide headwinds in the craft beer segment are negatively impacting beverage revenue.
Economic and Competitive Pressures: Competitive pricing pressures in the distribution business and challenges in the club retail channel for wellness products are affecting margins and revenue.
Regulatory Uncertainty in the U.S.: Potential regulatory changes affecting hemp-derived THC products after 2026 could impact the U.S. market.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Cannabis Rescheduling in the U.S.: Tilray is prepared to act immediately on cannabis rescheduling to Schedule III in the U.S., which is expected to lead to a federally compliant medical cannabis framework. The company has the platform, regulatory experience, and leadership team in place to scale operations.
International Cannabis Revenue Growth: Tilray expects continued momentum in international cannabis revenue, particularly in Europe (Germany, U.K., Poland). The company plans to expand its global footprint and improve operational efficiency through process improvements, automation, and increased utilization of cultivation facilities.
Medical Cannabis Distribution Expansion: Tilray aims to triple its medical cannabis distribution footprint in fiscal 2026 by expanding its pharmacy reach in Germany and leveraging strategic partnerships.
Canadian Cannabis Market: Tilray plans to elevate its Canadian cannabis business in the second half of 2026 and beyond by focusing on product mix, healthy margins, and innovation in high-growth segments like vapes and infused pre-rolls.
Beverage Business Growth: Tilray anticipates revenue improvements in the beverage segment in Q4 2026 due to spring product resets, new innovations, and strategic partnerships. The company is also prepared to produce and sell THC beverages in the U.S. if federally legalized.
Wellness Business Expansion: Tilray plans to expand its wellness business by focusing on value-added innovation, high-protein products, and clean energy drinks. The company is also exploring international growth opportunities in Asia and North America.
Adjusted EBITDA Guidance: Tilray reaffirms its fiscal 2026 adjusted EBITDA guidance of $62 million to $72 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:On the intoxicating hemp bans for November implementation, is there anything the industry can do to improve the regulatory outcome?
A:Irwin Simon stated that the company is working with congressmen, senators, and lobbyists to either extend the deadline or change regulations to allow a regulated amount of milligrams (e.g., 5 or 10 mg) to be sold nationally. He expressed optimism as there is little opposition to this effort, except from Senator McConnell and his supporters. He also highlighted the potential job losses if the ban is implemented.
Q:Regarding holding back supply and shifting it into international markets, does this mean sales that could have been in this quarter will come later? Can you quantify how much was held back?
A:Carl Merton explained that they held back from the Canadian wholesale market due to lower pricing compared to the prior year. Last year, they did about $5 million in this market. The inventory will be redeployed into European markets over the next six months for better margins. Irwin Simon added that this strategy allows them to achieve higher margins in Europe compared to selling in the wholesale market.
Q:What drove the 6% growth in Canadian adult-use cannabis in the quarter? Was it volume growth or price mix? Did you gain market share?
A:Irwin Simon clarified that the growth was not due to price but rather new distribution and demand. The company gained a small market share and sold 5.5 million units, the highest ever in a quarter. He noted that price compression has stabilized, and demand for Tilray's products, including flowers, pre-rolls, edibles, vapes, and drinks, continues to grow.
Q:What drove the substantial increase in distribution sales? Was there any timing benefit realized in the quarter?
A:Irwin Simon attributed the growth to the performance of CC Pharma, which had its most profitable quarter ever. The company is leveraging its European team to sell cannabis into pharmacies and improve margins through better buying power and demand for regular medicines. They are also exploring expansion into other countries.
Q:What is the timing expectation for Tilray Global Medical to approach $150 million? What are the risks from regulatory changes in Germany and pricing pressure for 2026?
A:Irwin Simon stated that the $150 million run rate is based on current annualized performance, with most revenue coming from international markets. He is not concerned about regulatory changes in Germany and believes demand will continue to grow. While price compression is a factor, Tilray's quality products and established presence in Germany provide a competitive edge.
Q:What are your expectations for growth in the Canadian market for 2026? Did a slowdown in growth influence the decision to shift some product internationally?
A:Irwin Simon expects mid- to high single-digit growth in the Canadian market. He emphasized the focus on profitable growth through value-added and premium products. The decision to shift product internationally was influenced by higher margins and the absence of excise tax in international markets. He also highlighted the company's strong supply capabilities and new product launches.
Q:Can you provide more color on CC Pharma's business and its potential role under new German regulations? Would you consider selling other companies' products through CC Pharma?
A:Irwin Simon explained that CC Pharma has been modernized and is now more efficient, with better buying power and margins. The company is leveraging CC Pharma's sales organization to sell more medical cannabis in Germany. While they currently focus on their own products, they may consider selling competitors' products if it makes business sense.
Q:Why has the beer business underperformed, and how does it fit into Tilray's long-term cannabis strategy?
A:Irwin Simon acknowledged the challenges in integrating multiple acquisitions and turning around underperforming brands. Despite current underperformance, he remains confident in the long-term potential of the beverage business, citing its role in a diversified portfolio and future opportunities in cannabis-infused drinks. He emphasized the importance of the beverage category and Tilray's infrastructure for future growth.
Q:Does the potential rescheduling of cannabis in the U.S. change Tilray's investment strategy in state-legal cannabis businesses?
A:Irwin Simon stated that Tilray remains focused on medical cannabis and plans to leverage its expertise, infrastructure, and research capabilities. The company is not looking at state-by-state recreational markets but is committed to developing FDA-approved cannabis drugs for medical use.
Q:What are the main international markets for cannabis outside of Germany, and are there any anticipated regulatory changes in other markets?
A:Irwin Simon identified Poland, Italy, the U.K., France, and Spain as key international markets. He also mentioned potential opportunities in the Middle East and India. He noted that the U.S. rescheduling of cannabis has positively influenced other countries' perceptions and regulatory approaches.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the question about whether the potential rescheduling of cannabis in the U.S. would lead to federal legalization or remain a state-by-state program. Irwin Simon's response focused on Tilray's medical cannabis strategy without clarifying the broader implications of rescheduling.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Africa beverage
America Asia
America protein
American
Canada regulation
Tilray Medical
Tilray term
afternoon
alcohol
approach
beverage market
beverage wellness
cannabis Tilray
cannabis product
care professional
fundamental
health care
industry Canada
insight
leader
liquidity
liquor
market Tilray
milligram
momentum
objective
operation
optimization
partnership
phase cannabis
process
producer
reform
regulator
reschedule cannabis
science
support
system
tax revenue
track
trajectory
value
vodka
wellness product
TLRY Transcript
Tilray Brands, Inc. (TLRY) Q3 2026 Earnings Call Transcript
Positive4-1
The earnings call summary and Q&A reflect a positive sentiment overall. The company shows strong international growth, particularly in Europe, and is expanding its distribution footprint. The strategic partnerships and product innovations in the beverage and wellness segments are promising. Despite some uncertainties in cost management and market projections, the reaffirmed EBITDA guidance and strategic plans for cannabis rescheduling in the U.S. and international expansion are positive indicators. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8%.
Aritzia Inc. (ATZ:CA) Q3 2026 Earnings Call Transcript
Positive1-8
Earnings results show strong financial performance with significant growth in gross profit, EBITDA, and cash position. The successful app launch and international expansion plans further support a positive outlook. Despite some uncertainties in guidance, the overall sentiment from the Q&A is optimistic, with plans for store openings and margin expansion. Given the company's market cap, the stock is likely to experience a positive movement between 2% to 8% over the next two weeks.
Tilray Brands, Inc. (TLRY) Q2 2026 Earnings Call Transcript
Positive1-8
The earnings call highlights several positive elements: strong growth in Canadian and European markets, strategic international expansion, and a focus on higher-margin opportunities. The Q&A session further supports this with insights into market share gains, price stabilization, and a promising outlook for CC Pharma. Despite some challenges in the beer segment, the company's diversified strategy and international growth potential present a positive sentiment. Given the market cap, these factors suggest a likely positive stock price movement in the short term.
Tilray Brands, Inc. (TLRY) Q1 2026 Earnings Call Transcript
Positive10-9
The earnings call summary reveals positive financial performance with revenue growth across segments, improved cash flow, and strong liquidity. The Q&A section highlights management's proactive strategies in addressing international growth challenges, potential U.S. market opportunities, and leveraging digital assets. Despite some unclear responses, the overall sentiment is positive, supported by market expansion plans, particularly in Europe and the U.S. The market cap suggests moderate volatility, leading to a prediction of a 2% to 8% stock price increase over the next two weeks.
TLRY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
